DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the global Product Engineering Services Market size is projected to reach 1,800.45 billion...
OSLO, Norway, July 14, 2025 /PRNewswire/ -- The announced Extraordinary General Meeting of Navamedic ASA was held today at 13.00 CET. All items on the...
ESPOO, Finland, July 14, 2025 /PRNewswire/ -- Normet is proud to announce the appointment of Claudia Hernandez as Director of Tunnellng Americas, further reinforcing...
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- The report "Cast Elastomers Market by Type (Hot Cast Elastomers and Cold Cast Elastomers), End-use Industry...
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- The report "Cast Elastomers Market by Type (Hot Cast Elastomers and Cold Cast Elastomers), End-use Industry...
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- The report "Microcrystalline Cellulose Market by Source (Wood based, non-wood based), by Application (Food & Beverage,...
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- The report "Microcrystalline Cellulose Market by Source (Wood based, non-wood based), by Application (Food & Beverage,...
STOCKHOLM, July 14, 2025 /PRNewswire/ -- Skanska has signed a contract with Fazer to build their new chocolate factory in Lahti, Finland. The contract...
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC).
Saint Herblain (France), le 11 juillet 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) allait lever sa restriction temporaire sur la vaccination des personnes âgées de 65 et plus avec le vaccin à dose unique contre le chikungunya IXCHIQ® de Valneva suite à l’achèvement d’une revue complète du vaccin par le comité pour l’évaluation des risques en matière de pharmacovigilance de l’EMA (PRAC).
NEW YORK, July 11, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global high-speed cables market is observing...
NEW YORK, July 11, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global high-speed cables market is observing...
DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025...